NextCure (NXTC) to Post Quarterly Earnings on Thursday

NextCure (NASDAQ:NXTC) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($1.98) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. On average, analysts expect NextCure to post $-8 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

NextCure Stock Performance

Shares of NASDAQ:NXTC opened at $5.02 on Thursday. NextCure has a 52-week low of $1.55 and a 52-week high of $15.74. The company has a market capitalization of $18.12 million, a PE ratio of -0.29 and a beta of 1.42. The company has a fifty day moving average of $3.66 and a 200-day moving average of $8.77.

Insider Transactions at NextCure

In related news, major shareholder Adar1 Capital Management, Llc bought 7,798 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was acquired at an average cost of $5.00 per share, with a total value of $38,990.00. Following the transaction, the insider directly owned 383,456 shares in the company, valued at approximately $1,917,280. This trade represents a 2.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders acquired 17,608 shares of company stock worth $87,720. 11.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On NextCure

Several institutional investors and hedge funds have recently made changes to their positions in NXTC. Marshall Wace LLP acquired a new position in shares of NextCure in the fourth quarter worth approximately $160,000. Millennium Management LLC acquired a new stake in NextCure during the 4th quarter valued at approximately $185,000. Geode Capital Management LLC increased its position in NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares during the period. Cable Car Capital LP raised its holdings in NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after purchasing an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares during the period. Institutional investors and hedge funds own 42.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of NextCure in a research report on Wednesday, July 15th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.